BMB-202

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BMB-202 is a selective serotonin 5-HT 2A receptor agonist and psychedelic drug of the N-benzylphenethylamine family which is under development for the treatment of depressive disorders and post-traumatic stress disorder (PTSD). It is taken orally.

BMB-202 is a selective serotonin 5-HT 2A receptor agonist and psychedelic drug of the N-benzylphenethylamine family which is under development for the treatment of depressive disorders and post-traumatic stress disorder (PTSD). It is taken orally.

Pharmacology

Pharmacodynamics

BMB-202 acts as a highly selective full agonist of the serotonin 5-HT 2A receptor. In terms of values, it shows 36- to 40-fold selectivity for activation of the serotonin 5-HT 2A receptor over the serotonin 5-HT 2C receptor and 500-fold selectivity for activation of the serotonin 5-HT 2A receptor over the serotonin 5-HT 2B receptor. It has been claimed by its developer that BMB-202 is the most selective serotonin 5-HT 2A receptor agonist yet to be discovered or to be in development, at least as of late 2024.

BMB-202 induces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in animals. Hence, it is putatively hallucinogenic in humans. As with other psychedelics like psilocybin, the HTR induced by BMB-202 shows a biphasic or inverted U-shaped dose–response curve. The drug shows a pharmacokinetic profile of high peak levels, rapid metabolic clearance, and a short elimination half-life in animals. It is predicted that BMB-202 will have a short half-life of less than 2 hours and short duration of 1 to 2 hours in humans.

In relation to this, the drug is described as a "fast-on-fast-off" compound. The expected short duration of BMB-202 is analogous to the short duration of dimethyltryptamine (DMT). Short-acting psychedelics like DMT and BMB-202 may be more suitable for use in clinical therapeutic settings. BMB-202 is also described as having rapid absorption and brain distribution, high bioavailability, and significant first-pass metabolism resulting in it being fast-acting and having a short duration.

Chemistry

of the N-benzylphenethylamine family with the same preclinical pharmacology as BMB-202 patented by Bright Minds Biosciences. The exact chemical structure of BMB-202 does not yet appear to have been disclosed. However, it is known to be an N-benzylphenethylamine derivative. In addition, selective serotonin 5-HT 2A receptor agonists of the N-benzylphenethylamine family have been patented by Bright Minds Biosciences, for instance lead agent "compound 109" (N-(2-methylthiobenzyl)-2-hydroxy-4-cyanophenethylamine).

Research

BMB-202 is under development by Bright Minds Biosciences. As of September 2025, it is in the preclinical research stage of development for treatment of depressive disorders and PTSD.

See also

List of investigational hallucinogens and entactogens Substituted N-benzylphenethylamine BMB-101 BMB-105 BMB-201

References

External links

Pipeline - Bright Minds Biosciences

Text derived from https://en.wikipedia.org/w/index.php?oldid=1356285911 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

9 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.